Table II.

Outcomes of RIC HCT for HLH.

Reference	N	Predominant RIC Regimen	MRD/MUD	MMRD/MMUD	Haplo	Engrafted (%)	Mixed Chimerism (%)	Graft-Related Acute GVHD (I-IV or II-IV)	HLH post-HCT (%)	VOD (%)	Death Prior to Day +100	Predominant Causes of Death	Survival (years)
Cooper et al (2006)	12	Alem, Flu, Mel *Haplos received ATG instead of alem, and also busulfan	50%	25%	25%	100%	33%	33%	Not Specified	0%	Not Specified	Pneumonitis	75% (30-month Median Follow-Up)
Cooper et al (2008)	25	Alem, Flu, Mel *Haplos received ATG instead of alem, and also busulfan	40%	44%	16%	100%	29%	Not Specified	0%	0%	Not Specified	Pneumonitis	84% (3- year Median Follow-Up)
Marsh et al (2010b)	26	Alem, Flu, Mel	73%	27%	0%	100%	65%	8%	4%	0%	0%	Infection, GVHD	92% (3-year POS)

RIC Reduced intensity conditioning

MRD Matched related donor

MUD Matched unrelated donor

MMRD Mismatched related donor

MMUD Mismatched unrelated donor

Haplo Haploidentical

GVHD Graft-versus-host disease

HLH Haemophagocytic lymphohistiocytosis

HCT Haematopoietic cell transplantation

VOD (hepatic) Veno-occlusive disease

Alem Alemtuzumab

Flu Fludarabine

Mel Melphalan

POS Probability of survival